loading
Aurinia Pharmaceuticals Inc stock is traded at $8.865, with a volume of 138.63K. It is down -0.67% in the last 24 hours and up +2.66% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$8.93
Open:
$8.95
24h Volume:
138.63K
Relative Volume:
0.10
Market Cap:
$1.20B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-16.73
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
+2.90%
1M Performance:
+2.66%
6M Performance:
+7.65%
1Y Performance:
+56.16%
1-Day Range:
Value
$8.815
$8.96
1-Week Range:
Value
$8.55
$9.36
52-Week Range:
Value
$5.195
$10.67

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name
Name
Aurinia Pharmaceuticals Inc
Name
Phone
250-744-2487
Name
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Name
Employee
300
Name
Twitter
@AuriniaPharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
AUPH's Discussions on Twitter

Compare AUPH with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
AUPH
Aurinia Pharmaceuticals Inc
8.865 1.21B 175.51M -78.02M -34.18M -0.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.16 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
566.88 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.73 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.91 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
297.15 31.54B 3.81B -644.79M -669.77M -6.24

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-04-22 Downgrade Oppenheimer Outperform → Perform
May-05-22 Resumed Cantor Fitzgerald Overweight
Dec-10-21 Upgrade Oppenheimer Perform → Outperform
Oct-28-21 Downgrade Oppenheimer Outperform → Perform
Jan-25-21 Reiterated H.C. Wainwright Buy
Nov-03-20 Reiterated H.C. Wainwright Buy
Jun-17-20 Initiated BTIG Research Buy
May-05-20 Initiated Cowen Outperform
Jan-10-20 Initiated Jefferies Buy
Dec-16-19 Reiterated H.C. Wainwright Buy
Mar-16-18 Reiterated Cantor Fitzgerald Overweight
Feb-08-18 Initiated RBC Capital Mkts Outperform
Oct-30-17 Reiterated H.C. Wainwright Buy
May-18-17 Reiterated H.C. Wainwright Buy
Apr-11-17 Initiated Cantor Fitzgerald Overweight
Mar-22-17 Reiterated FBR & Co. Outperform
Dec-30-16 Reiterated H.C. Wainwright Buy
Aug-17-16 Reiterated H.C. Wainwright Buy
Jun-30-16 Initiated H.C. Wainwright Buy
May-08-15 Initiated MLV & Co Buy
View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

pulisher
05:08 AM

Does Aurinia Pharmaceuticals Inc. stock perform well during market downturnsSuperior portfolio returns - jammulinksnews.com

05:08 AM
pulisher
01:37 AM

Why is Aurinia Pharmaceuticals Inc. stock attracting strong analyst attentionMaximize your portfolio’s earning power - jammulinksnews.com

01:37 AM
pulisher
Jul 27, 2025

What is the risk reward ratio of investing in Aurinia Pharmaceuticals Inc. stockGet professional advice for market timing - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Aurinia Pharmaceuticals Inc. a growth stock or a value stockAchieve breakthrough investment performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Should I hold or sell Aurinia Pharmaceuticals Inc. stock in 2025Skyrocketing returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What is Aurinia Pharmaceuticals Inc. company’s growth strategyUnlock powerful portfolio optimization tools - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What makes Aurinia Pharmaceuticals Inc. stock price move sharplyAccelerated wealth expansion - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 26, 2025

Can Aurinia Pharmaceuticals Inc. stock recover from recent decline200 Percent Gain Alert - Metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastFastest-growing stock picks - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Will Aurinia Pharmaceuticals Inc. stock split in the near futureMarket-leading growth rates - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Aurinia Pharmaceuticals Inc. stockRapid growth opportunities - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

When is the best time to buy Aurinia Pharmaceuticals Inc. stockSuperior profit margins - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Aurinia Pharmaceuticals Inc. a good long term investmentTremendous gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Aurinia Pharmaceuticals Inc. stock priceUnmatched profit growth - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - Zenopa

Jul 24, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co

Jul 22, 2025
pulisher
Jul 20, 2025

(AUPH) Technical Data - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 18, 2025

Aurinia Pharmaceuticals (NASDAQ:AUPH) Delivers Shareholders Favorable 52% Return Over 1 Year, Surging 5.5% in the Last Week Alone - 富途牛牛

Jul 18, 2025
pulisher
Jul 17, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo

Jul 17, 2025

Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Greenleaf Peter
Chief Executive Officer
Mar 03 '25
Sale
8.00
195,593
1,564,744
1,953,892
Greenleaf Peter
Chief Executive Officer
Mar 04 '25
Sale
7.92
164,947
1,306,380
1,788,945
Keenan Greg
Chief Medical Officer
Mar 03 '25
Sale
8.00
12,239
97,912
161,789
Miller Joseph M
Chief Financial Officer
Mar 03 '25
Sale
8.00
61,859
494,872
633,515
Miller Joseph M
Chief Financial Officer
Mar 04 '25
Sale
7.92
56,154
444,740
577,361
Robertson Stephen P.
EVP, General Counsel
Mar 03 '25
Sale
8.00
64,872
518,976
566,883
Robertson Stephen P.
EVP, General Counsel
Mar 04 '25
Sale
7.92
57,607
456,247
509,276
Donley Matthew Maxwell
Chief Operating Officer
Mar 03 '25
Sale
8.00
65,902
527,216
739,456
Donley Matthew Maxwell
Chief Operating Officer
Mar 04 '25
Sale
7.92
58,991
467,209
680,465
TANG KEVIN
Director
Mar 04 '25
Buy
7.96
748,038
5,953,304
10,029,500
$23.31
price down icon 0.43%
$36.92
price up icon 0.55%
$103.78
price down icon 0.16%
$28.06
price down icon 2.32%
$114.70
price down icon 0.48%
biotechnology ONC
$297.11
price up icon 1.68%
Cap:     |  Volume (24h):